LivaNova PLC

LivaNova PLC

  • Price (USD)55.69
  • Today's Change-0.47 / -0.84%
  • Shares traded225.31k
  • 1 Year change-32.32%
  • Beta0.8650
Data delayed at least 15 minutes, as of Dec 02 2022 21:00 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

LivaNova PLC is a medical device company focused on the development and delivery of important products and therapies for the benefit of patients, healthcare professionals and healthcare systems throughout the world. The Company designs, develops, manufactures and sells products and therapies to provide improvements for both the head and heart. The Company operates in three reportable segments: Cardiopulmonary, Neuromodulation and Advanced Circulatory Support. Its Cardiac Surgery Business Franchise (CS) is engaged in the development, production and sale of cardiac surgery products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and other accessories used for extracorporeal circulation, systems for autologous blood transfusion and blood washing. Its Neuromodulation Business Franchise designs develops and markets neuromodulation-based medical devices for the treatment of epilepsy and difficult-to-treat depression (DTD) and obstructive sleep apnea.

  • Revenue in USD (TTM)1.02bn
  • Net income in USD-96.47m
  • Incorporated2015
  • Employees3.00k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
LIVN:NSQ since
ALung Technologies IncDeal completed02 May 202202 May 2022Deal completed-27.35%110.00m
Data delayed at least 15 minutes, as of Dec 02 2022 21:00 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Procept Biorobotics Corp49.69m-68.82m2.05bn234.00--8.55--41.31-1.56-1.561.135.370.19822.026.20212,367.50-27.45---29.34--50.18---138.49--15.27-11.260.1744--346.72---12.89------
NuVasive, Inc.1.20bn-20.41m2.09bn2.90k--2.5016.361.74-0.4583-0.458321.9515.980.55631.015.51413,299.30-0.94710.3758-1.190.449972.5372.00-1.700.67060.72021.640.51720.008.413.43-72.49--3.59--
AtriCure Inc.315.57m-56.04m2.14bn875.00--4.74--6.77-1.23-1.236.929.700.52821.938.42360,650.30-9.38-3.47-10.35-3.8174.7473.42-17.76-7.462.92-13.310.1353--32.8312.08204.24--4.86--
Glaukos Corp284.88m-89.61m2.32bn727.00--4.23--8.15-1.90-1.905.9511.510.27492.558.14391,850.10-8.65-6.01-9.20-6.4875.9177.83-31.45-15.286.84-8.010.3918--30.7020.7858.79--50.07--
Helen of Troy Limited2.24bn170.74m2.43bn2.15k14.391.7411.531.097.047.0492.3858.340.79512.024.781,042,
Integer Holdings Corp1.32bn68.26m2.45bn9.00k36.161.8115.561.862.052.1639.5240.900.51775.415.02146,298.702.682.912.893.1326.1128.705.186.221.742.830.40920.0013.752.5720.4030.18-1.83--
Pacific Biosciences of California Inc136.97m-299.19m2.51bn728.00--3.99--18.29-1.34-1.340.61372.770.07112.475.87188,145.60-15.53-22.10-16.10-24.5744.2939.32-218.44-91.1810.66-19.580.5886--65.437.55-716.34---6.29--
Conmed Corp1.07bn-82.72m2.67bn3.80k--3.72--2.49-2.91-2.9134.7223.500.52821.775.89281,203.90-4.092.11-4.532.3655.9355.04-7.743.661.293.630.591469.2617.185.77557.1633.650.15270.00
Tandem Diabetes Care Inc790.71m-67.93m2.74bn2.00k--6.49--3.47-1.06-1.0612.316.560.83334.457.90395,356.00-7.16-15.69-8.47-19.8452.0052.00-8.59-15.674.20-19.110.4013--40.8952.85145.27--21.36--
Patterson Companies, Inc.6.41bn193.80m2.80bn7.70k14.602.7110.210.43641.971.9765.1510.592.336.1817.23832,181.106.98-0.182811.32-0.269120.6521.183.00-0.09680.7965--0.3816--9.933.0530.283.18-4.021.20
STAAR Surgical Company279.35m37.82m2.85bn692.0077.178.9068.0410.200.76630.76635.666.640.77673.335.74403,682.1010.525.8312.067.0878.2574.4413.546.986.1110.260.00130.0041.0022.83314.36--33.61--
LivaNova PLC1.02bn-96.47m3.01bn3.00k--2.62--2.96-1.81-1.8118.9121.430.46062.415.74338,998.30-4.37-5.98-5.56-7.3470.9265.94-9.48-14.042.530.81950.3201--10.821.4260.90---7.86--
Adapthealth Corp2.89bn86.96m3.05bn10.70k35.521.417.181.050.63650.636515.5216.080.554721.188.20270,319.401.88--2.08--17.53--3.39--1.082.750.504--132.35--187.73------
Inmode Ltd431.24m176.50m3.17bn362.0018.496.2417.917.362.,191,271.0034.3837.6438.5945.4883.9285.2640.9338.019.12828.050.000.0073.4972.99119.87245.3137.94--
Axonics Inc240.92m-75.53m3.51bn517.00--6.38--14.57-1.66-1.665.2811.110.40371.117.58465,994.20-12.66-25.46-13.67-28.7070.6062.16-31.35-86.626.44-52.960.00--61.64---45.80--50.57--
ICU Medical Inc2.04bn-38.83m3.90bn8.50k--1.9423.901.91-1.57-1.5787.5083.940.64953.0412.42240,295.10-1.235.01-1.385.7631.8436.98-1.905.991.171.020.45150.003.5628.2518.7210.3327.02--
Data as of Dec 02 2022. Currency figures normalised to LivaNova PLC's reporting currency: US Dollar USD

Institutional shareholders

49.50%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 30 Sep 20225.67m10.58%
PRIMECAP Management Co.as of 30 Sep 20224.58m8.55%
Harris Associates LPas of 30 Sep 20223.59m6.71%
SSgA Funds Management, Inc.as of 30 Sep 20222.56m4.78%
Barrow, Hanley, Mewhinney & Strauss LLCas of 30 Sep 20222.44m4.55%
Eminence Capital LPas of 30 Sep 20222.09m3.90%
Redmile Group LLCas of 30 Sep 20221.54m2.87%
Sachem Head Capital Management LPas of 30 Sep 20221.54m2.87%
Hawk Ridge Capital Management LPas of 30 Sep 20221.28m2.39%
The Vanguard Group, Inc.as of 30 Sep 20221.24m2.32%
More ▼
Data from 30 Sep 2022 - 30 Sep 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.